- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ... Cited by 179 - Related articles - All 25 versions
DJ Drucker - Nature Clinical Practice Endocrinology and Metabolism, 2005 - glucagon.com INTRODUCTION Before the cDNAs and genes encoding pro glucagon were cloned, pancreatic
glucagon was the prin- cipal proglucagon-derived peptide (PGDP) with well-characterized biologic
actions. However, antisera directed against glucagon detected not only circulating ... Cited by 60 - Related articles - View as HTML - BL Direct - All 6 versions
C Alarcon, B Wicksteed, CJ Rhodes - Diabetologia, 2006 - Springer Abstract Aims/hypothesis Ideally, a therapeutic insulin secretagogue should coordinately increase
insulin production and insulin secretion to maintain islet beta cell secretory capacity. We compared
the incretin mimetic exendin 4 and the sulfonylurea glibenclamide (known as glyburide in ... Cited by 21 - Related articles - BL Direct - All 4 versions
- ►endojournals.org CA Syme, L Zhang, A Bisello - Molecular Endocrinology, 2006 - Endocrine Soc The glucagon-like peptide 1 receptor (GLP-1R) mediates important effects on ß-cell function
and glucose homeostasis and is one of the most promising therapeutic targets for type 2, and
possibly type 1, diabetes. Yet, little is known regarding the molecular and cellular ... Cited by 17 - Related articles - BL Direct - All 4 versions
B Ahrén - Therapy, 2005 - Future Medicine Glucagon-like peptide-1 is an incretin hormone with antidiabetic action due to stimulation of insulin
secretion, and potentially also to an increase in β-cell mass, inhibition of glucagon secretion,
delay in gastric emptying and induction of satiety. A problem in developing glucagon-like ... Cited by 8 - Related articles - BL Direct - All 5 versions
OA Roges, M Baron, A Philis- … - Expert Opin. Investig. …, 2005 - informahealthcare.com The incretin effect is a phenomenon in which enteral glucose administration provokes greater
insulin secretion than intravenous administration. The main incretins, glucose-dependent insulinotropic
peptide and glucagon-like pep- tide (GLP)-1 are defective in Type 2 diabetes; whereas ... Cited by 8 - Related articles - BL Direct - All 4 versions
JA Koehler, DJ Drucker - Diabetes, 2006 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 promotes β-cell proliferation and survival through stimulation
of its specific G-protein–coupled receptor; however, the potential for GLP-1 receptor
(GLP-1R) agonists to promote growth and proliferation of human pancreatic-derived cells ... Cited by 6 - Related articles - BL Direct - All 9 versions
LL Baggio, D Holland, J Wither, DJ Drucker - Diabetes, 2006 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) exhibits considerable potential for the treatment of type 2 diabetes
because of its effects on stimulation of insulin secretion and the inhibition of gastric
emptying, appetite, and glucagon secretion. However, native GLP-1 undergoes rapid ... Cited by 4 - Related articles - BL Direct - All 6 versions
N Irwin, PL McClean, RS Cassidy, FPM O'Harte, … - DIABETES METABOLISM …, 2007 - qub.ac.uk Diabetes Metab Res Rev 2007; 23: 572–579. Published online 21 February 2007 in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/dmrr.729 ... Comparison of the anti-diabetic effects
of GIP- and ... GLP-1-receptor activation in obese diabetic (ob/ob) Cited by 2 - Related articles - View as HTML - BL Direct - All 3 versions
